Metabolomics Global Market Report 2024

The metabolomics market size has grown rapidly in recent years. It will grow from $3.11 billion in 2023 to $3.6 billion in 2024 at a compound annual growth rate (CAGR) of 15.8%. The growth observed in the historical period can be attributed to several key factors, including advancements in healthcare, drug discovery and development, the identification of disease biomarkers, the contributions of academic and research institutions, and the progress made in the fields of nutrition and food science.

The metabolomics market size is expected to see rapid growth in the next few years. It will grow to $6.68 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. The anticipated growth in the forecast period can be attributed to several key factors, including the increasing emphasis on personalized healthcare, the focus on drug safety and efficacy, the significance of microbiome and gut health research, the expanding applications in environmental and agriculture sectors, and the developments in regenerative medicine. Significant trends expected in the forecast period encompass the integration of metabolomics with other omics fields, the rise of targeted metabolomics approaches, the emergence of single-cell metabolomics techniques, the utilization of data analytics and artificial intelligence (AI), and the growing adoption of point-of-care testing in metabolomics applications.

The increasing incidence of cancer is a primary driver of growth within the metabolomics market. Metabolomics, which scrutinizes potential biomarkers to assess cancer drug responsiveness, plays a vital role in early cancer diagnosis. For example, according to a report by WebMD in 2021, approximately 10 million people globally succumbed to cancer. Furthermore, the American Cancer Society's January 2022 report anticipates 1.9 million new cases of cancer and 609,360 cancer-related deaths in the United States in 2022. Metabolomics methodologies, including nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques, are pivotal in studying cancer. Companies like Metabolon Inc. and Bruker Corp. have integrated metabolomics to aid in early cancer detection and treatment.

The key products and services in the field of metabolomics encompass metabolomics instruments, metabolomics bioinformatics tools, and various services. Metabolomics instruments are specialized devices employed to comprehensively analyze low-molecular-weight compounds within biological samples. These instruments include separation techniques, detection methodologies, and metabolomics bioinformatics tools and services, which involve databases and bioinformatics tools. Metabolomics finds application in diverse medical indications such as cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. These applications are utilized for purposes such as biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and more.

The metabolomics market research report is one of a series of new reports that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rising prevalence of chronic diseases is poised to drive the metabolomics market's growth in the foreseeable future. Chronic ailments persist for a year or longer, necessitating ongoing medical intervention and often hindering daily activities. Metabolomics plays a crucial role in uncovering the metabolic underpinnings of chronic diseases, identifying pertinent biomarkers, and pinpointing potential targets for alternative therapies. Its ability to directly connect with an organism's phenotype makes it an invaluable tool in disease and health research. As highlighted in a March 2022 report by the Australian Bureau of Statistics, nearly three-quarters of Australians (78.6%) reported at least one long-term health issue, with almost half of the population (46.6% or 11.6 million individuals) affected by chronic conditions. Hence, the increasing prevalence of chronic diseases is a driving force behind the expansion of the metabolomics market.

The burgeoning complexity in interpreting data acts as a constraint impeding the growth of the metabolomics market. Metabolomics tools yield extensive data through techniques like nuclear magnetic resonance (NMR) spectroscopy, used for metabolic profiling, which measures and interprets various low molecular weight and other intermediates. This dynamically changing and voluminous data poses challenges in interpretation. Sophisticated statistical techniques are essential for data classification and analysis to extract biological insights, which can be time-consuming and costly, thereby restraining the growth of the metabolomics market.

The integration of machine learning is increasingly popular within the metabolomics field, significantly enhancing the efficiency of interpreting data obtained from metabolomics techniques. Machine learning-powered technologies automate complex and risky processes, streamline tasks, and offer swift, error-free services. Industry companies are favoring machine learning techniques for metabolism analysis, solving problems, and executing tasks. Various machine learning algorithms aid in metabolism data analysis and modeling metabolic pathways. Companies like Bio-Rad Laboratories, Metabolon Inc., among others, are leveraging machine learning algorithms to enhance understanding and prediction in metabolomics research. For example, MeltDB 2.0, a machine learning software utilized for metabolomics experiment data analysis and integration, provides robust research support, storing experimental datasets, and comprehensive analysis and visualization features to represent large and complex data effectively.

Key players in the metabolomics market are strategically focusing on partnerships to better address the needs of their consumers. An exemplary collaboration is the initiative between Thermo Fisher Scientific Inc. and the University of California, establishing the Center of Excellence in Clinical Metabolomics. This partnership aims to advance metabolomics science by standardizing community efforts, fostering large-scale cohort studies, and clinical research. In July 2021, Thermo Fisher Scientific Inc., in partnership with the University of California, inaugurated the Center of Excellence in Clinical Metabolomics, dedicated to large-scale population-based metabolic analysis for transformative research and personalized medicine. The center's standardized procedures include end-to-end metabolic profiling workflows, customized chromatography-mass spectrometry (LC-MS) techniques, analytical controls to ensure instrument efficiency, and comprehensive training for metabolomics personnel, scientists, and core lab managers. The University of California is a US-based public grant research university.

In October 2022, Clinical Microbiomics, a Denmark-based microbiome research company, acquired MS-Omics, a Denmark-based metabolomics company, for an undisclosed sum. This acquisition bolstered Clinical Microbiomics' portfolio by adding specialized metabolic profiling offerings. The addition of MS-Omics' capabilities is set to advance Clinical Microbiomics' systems biology platform, benefiting researchers globally.

Major companies operating in the metabolomics market include Human Metabolome Technologies Inc., Metabolon Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Waters Corporation, Biocrates Life Sciences AG, Shimadzu Corporation, Danaher Corporation, Kore Technologies Ltd., Dani Instruments SpA, Perkinelmer Inc., Evans Analytical Group LLC, LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, Merck kgaA, Southern Research Company Inc., Alcami Corporation, Charles River Laboratories International Inc., Eremid Genomic Services LLC, Metabowerke GmbH, Metabolomic Diagnostics, Phenomenex Inc.

North America was the largest region in the metabolomics market in 2023. Western Europe was the second largest region in the metabolomics market. The regions covered in the metabolomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.